Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

被引：0

作者：

Matoba, Takuma ^{[1
]}

Minohara, Kiyoshi ^{[1
]}

Kawakita, Daisuke ^{[1
,7
]}

Sawabe, Michi ^{[2
]}

Takano, Gaku ^{[3
]}

Oguri, Keisuke ^{[4
]}

Murashima, Akihiro ^{[1
]}

Iwaki, Sho ^{[1
]}

Tsuge, Hiroshi ^{[1
]}

Imaizumi, Sae ^{[5
]}

Hojo, Wataru ^{[4
]}

Kondo, Ayano ^{[1
]}

Tsukamoto, Koji ^{[6
]}

Iwasaki, Shinichi ^{[1
]}

机构：

[1] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, Nagoya, Japan

[2] Toyota Kosei Hosp, Dept Otorhinolaryngol, Toyota, Japan

[3] Nagoya City Univ, Dept Otorhinolaryngol, West Med Ctr, Nagoya, Japan

[4] Anjo Kosei Hosp, Dept Otorhinolaryngol, Anjo, Japan

[5] Japanese Fdn Canc Res, Dept Head & Neck Surg, Canc Inst Hosp, Tokyo, Japan

[6] Aichi Canc Ctr Hosp, Dept Head & Neck Surg, Nagoya, Japan

[7] Nagoya City Univ, Dept Otorhinolaryngol Head & Neck Surg, Grad Sch Med Sci, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678601, Japan

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2024年 / 46卷 / 08期

基金：

日本学术振兴会;

关键词：

head and neck cancer; immune checkpoint inhibitor; immune-related adverse effects; paclitaxel monotherapy; salvage chemotherapy; SQUAMOUS-CELL CARCINOMA; COMBINATION; CETUXIMAB; PROGRESSION; PACLITAXEL; NIVOLUMAB;

D O I：

10.1002/hed.27643

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundIt is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC).MethodsThis study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen.ResultsOf the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS.ConclusionsSCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.

引用

页码：1855 / 1864

页数：10

共 50 条

[1] Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer
Fukuoka, Osamu
Saito, Yuki
Mukai, Toshiyuki
Hayashi, Takaaki
Yamamura, Koji
Sakai, Toshihiko
Kobayashi, Kenya
Akashi, Ken
Yoshida, Masafumi
Ando, Mizuo
Yamasoba, Tatsuya
[J]. LARYNGOSCOPE, 2024, 134 (01): : 228 - 235
[2] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Saleh, Khalil
Daste, Amaury
Martin, Nicolas
Pons-Tostivint, Elvire
Auperin, Anne
Herrera-Gomez, Ruth Gabriela
Baste-Rotllan, Neus
Bidault, Francois
Guigay, Joel
Le Tourneau, Christophe
Saada-Bouzid, Esma
Even, Caroline
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
[3] Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma
Fushimi, Chihiro
Okamoto, Isaku
Matsuki, Takashi
Masubuchi, Tatsuo
Okada, Takuro
Sato, Hiroki
Tsukahara, Kiyoaki
Kondo, Takahito
Yamashita, Taku
Hanyu, Kenji
Omura, Go
Takahashi, Hideaki
Tada, Yuichiro
Miura, Kouki
[J]. ANTICANCER RESEARCH, 2020, 40 (09) : 5277 - 5283
[4] Safety and efficacy of salvage radiotherapy after progression to checkpoint inhibitors in recurrent and/or metastatic head and neck cancer
Cabezas-Camarero, S.
Merino-Menendez, S.
Cabrera-Martin, M. N.
Cerezo-Druet, E.
Vazquez-Masedo, G.
Puebla, F.
Corona, J. A.
Perez-Segura, P.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1403 - S1403
[5] Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck
Kacew, Alec J.
Harris, Ethan J.
Lorch, Jochen H.
Schoenfeld, Jonathan D.
Margalit, Danielle N.
Kass, Jason, I
Tishler, Roy B.
Haddad, Robert, I
Hanna, Glenn J.
[J]. ORAL ONCOLOGY, 2020, 105
[6] Chemotherapy for recurrent/metastatic head and neck cancer
Moyano, A
[J]. 1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 983 - 991
[7] Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
Takuma Matoba
Kiyoshi Minohara
Daisuke Kawakita
Gaku Takano
Keisuke Oguri
Akihiro Murashima
Kazuyuki Nakai
Sho Iwaki
Hiroshi Tsuge
Nobukazu Tanaka
Sae Imaizumi
Wataru Hojo
Ayano Matsumura
Koji Tsukamoto
Shinichi Esaki
Shinichi Iwasaki
[J]. Scientific Reports, 12
[8] Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
Matoba, Takuma
Minohara, Kiyoshi
Kawakita, Daisuke
Takano, Gaku
Oguri, Keisuke
Murashima, Akihiro
Nakai, Kazuyuki
Iwaki, Sho
Tsuge, Hiroshi
Tanaka, Nobukazu
Imaizumi, Sae
Hojo, Wataru
Matsumura, Ayano
Tsukamoto, Koji
Esaki, Shinichi
Iwasaki, Shinichi
[J]. SCIENTIFIC REPORTS, 2022, 12 (01)
[9] Salvage chemotherapy after treatment with immune checkpoint inhibitors in women with recurrent cervical cancer
Wallam, Sara
Dugan, Katherine
Levinson, Kimberly
[J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (02) : 394 - 394
[10] CHEMOTHERAPY WITH GEFITINIB IN RECURRENT AND METASTATIC HEAD AND NECK CANCER
Gupta, D.
Rao, R.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : E4 - E4

← 1 2 3 4 5 →